Finder makes money from featured partners, but editorial opinions are our own.

How to buy AbbVie (ABBV) shares in Australia

Learn how to easily invest in AbbVie shares.

AbbVie
NYSE: ABBV-USD
About 30 minutes ago

$171.43

+$0.29 (+0.17%)

AbbVie Inc (ABBV) is a leading drug manufacturers - general business with stocks listed in the US. It opened the day at US$173.67 after a previous close of US$171.14. During the day the price has varied from a low of USD171.22 to a high of USD173.845. The latest price was USD171.43 (25 minute delay). AbbVie is listed on the NYSE. All prices are listed in US Dollars.

How to buy shares in AbbVie

  1. Compare share trading platforms. To buy shares in a company listed in the US from Australia you'll need to find a trading platform that offers access to US stock markets. Look for a platform with low brokerage and foreign exchange fees.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, which will typically include your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
  3. Search for AbbVie. Find the share by name or ticker symbol: ABBV. Research its history to confirm it's a solid investment that matches your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until AbbVie reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying using consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of US$171.14, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of AbbVie, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of AbbVie. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights.

AbbVie stock price (NYSE:ABBV)

Use our graph to track the performance of ABBV stocks over time.

AbbVie shares at a glance

Information last updated 2024-07-19.
OpenUS$173.67
HighUS$173.845
LowUS$171.22
CloseUS$171.43
Previous closeUS$171.14
Change US$0.29
Change % 0.1695%
Volume 1,750,172
Information last updated 2024-07-13.
52-week rangeUS$130.7454 - US$181.1978
50-day moving average US$165.0984
200-day moving average US$161.2614
Target priceUS$184.12
PE ratio 50.8299
Dividend yield US$6.06 (3.64%)
Earnings per share (TTM) US$3.35

AbbVie share growth calculator

US$

Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.

AbbVie price performance over time

Historical closes compared with the last close of $171.43

1 week (2024-07-12) 0.68%
1 month (2024-06-18) 0.04%
3 months (2024-04-19) 3.02%
6 months (2024-01-19) 4.04%
1 year (2023-07-19) 24.51%
2 years (2022-07-18) 14.62%
3 years (2021-07-19) 48.53%
5 years (2019-07-19) 150.12%

Compare trading platforms to buy AbbVie shares

Name Product Standard brokerage for US shares Currency conversion fee Asset class
eToro
Finder AwardExclusive
eToro
US$0
50-150 pips
ASX shares, Global shares, US shares, ETFs
Finder exclusive: Get 12 months of investment tracking app Delta PRO for free when you fund your eToro account (T&Cs apply).
CFD service. Capital at risk.
Join the world's biggest social trading network when you trade stocks, commodities and currencies from the one account.
Webull
Exclusive
Webull
US$0.25
0.50% (50 pips)
ASX shares, Global shares, Options trading, US shares, ETFs
Finder exclusive: Get an additional 30 days of $0 brokerage on stocks. T&Cs apply.
Trade over 3,300 Australian and US ETFs with real $0 brokerage.
Moomoo Share Trading
US$0.99
55 pips or 0.0055 AUD/USD
ASX shares, Global shares, US shares, ETFs
Get 10 free shares + earn 6.8% p.a. on idle cash upon deposit. T&Cs apply.
Trade shares on the ASX, the US markets and buy ETFs with Moomoo. Plus join a community over 20 million investors.
Tiger Brokers
Exclusive
Tiger Brokers
US$2
37 pips
ASX shares, Global shares, US shares, ETFs
Finder exclusive: 10 no-brokerage US or ASX market trades in the first 180 days + 7% p.a. on uninvested cash with first deposit of any amount, plus US$30 TSLA + US$30 NVDA shares with deposits up to AU$2000. T&Cs apply.
Trade Australian, US and Asian stocks with no minimum deposit on Tiger Broker’s feature-packed platform.
CMC Invest
Finder Award
CMC Invest
US$0
0.60%
ASX shares, Global shares, Options trading, US shares, ETFs
$0 brokerage on US, UK, Canadian and Japanese markets (FX spreads apply).
Trade over 45,000 shares and ETFs from Australia and 15 major global markets. Plus, buy Aussie shares or ETFs for $0 brokerage up to $1,000 (First buy order of each security, each day - excludes margin loan settled trades).
loading
The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.

Is it a good time to buy AbbVie stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Is AbbVie under- or over-valued?

Valuing AbbVie stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of AbbVie's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

AbbVie's P/E ratio

AbbVie's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 51x. In other words, AbbVie shares trade at around 51x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

AbbVie's PEG ratio

AbbVie's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.4488. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into AbbVie's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

AbbVie's EBITDA

AbbVie's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$26.1 billion (£20.2 billion).

The EBITDA is a measure of a AbbVie's overall financial performance and is widely used to measure stock profitability.

AbbVie share price volatility

Over the last 12 months, AbbVie's shares have ranged in value from as little as US$130.7454 up to US$181.1978. A popular way to gauge a stock's volatility is its "beta".

ABBV.US volatility(beta: 0.62)Avg. volatility(beta: 1.00)LowHigh

Beta measures a share's volatility in relation to the market. The market (NYSE average) beta is 1, while AbbVie's is 0.623. This would suggest that AbbVie's shares are less volatile than average (for this exchange).

AbbVie financials

Revenue TTM US$54.4 billion
Operating margin TTM 28.29%
Gross profit TTM US$41.5 billion
Return on assets TTM 7.71%
Return on equity TTM 56.24%
Profit margin 11.02%
Book value 4.535
Market capitalisation US$300.7 billion

TTM: trailing 12 months

AbbVie share dividends

56%

Dividend payout ratio: 55.93% of net profits

Recently AbbVie has paid out, on average, around 55.93% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3.64% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), AbbVie shareholders could enjoy a 3.64% return on their shares, in the form of dividend payments. In AbbVie's case, that would currently equate to about $6.06 per share.

AbbVie's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.

AbbVie's most recent dividend payout was on 14 August 2024. The latest dividend was paid out to all shareholders who bought their shares by 14 July 2024 (the "ex-dividend date").

AbbVie's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like AbbVie.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

AbbVie's total ESG risk score

Total ESG risk: 34.86

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and AbbVie's overall score of 34.86 (as at 12/31/2018) is pretty weak – landing it in it in the 66th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like AbbVie is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

AbbVie's environmental score

Environmental score: 4.96/100

AbbVie's environmental score of 4.96 puts it squarely in the 7th percentile of companies rated in the same sector. This could suggest that AbbVie is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

AbbVie's social score

Social score: 22.65/100

AbbVie's social score of 22.65 puts it squarely in the 7th percentile of companies rated in the same sector. This could suggest that AbbVie is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

AbbVie's governance score

Governance score: 16.25/100

AbbVie's governance score puts it squarely in the 7th percentile of companies rated in the same sector. That could suggest that AbbVie is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

AbbVie's controversy score

Controversy score: 3/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. AbbVie scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that AbbVie hasn't always managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

AbbVie Inc was last rated for ESG on: 2019-01-01.

Total ESG score 34.86
Total ESG percentile 65.78
Environmental score 4.96
Environmental score percentile 7
Social score 22.65
Social score percentile 7
Governance score 16.25
Governance score percentile 7
Level of controversy 3

AbbVie overview

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Frequently asked questions

More guides on Finder

Ask a question

You are about to post a question on finder.com.au:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com.au is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder only provides general advice and factual information, so consider your own circumstances, or seek advice before you decide to act on our content. By submitting a question, you're accepting our Terms Of Service and Finder Group Privacy & Cookies Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site